Please note that this is an English translation of a press release written in Swedish by Ortoma AB (publ), in the event of any inaccuracies, the Swedish version applies. The information was submitted for publication 2025-02-25.
Ortoma appoints Fredrik Strömberg as new CEO
Ortoma AB (publ) (“Ortoma” or the “Company”) hereby announces that the Board of Directors has appointed Fredrik Strömberg as the new CEO of the Company as of May 15, 2025.
Fredrik Strömberg, M.Sc. in Industrial Engineering and Management Intl. is an experienced leader with very long experience in MedTech. Over the past 20 years, Fredrik has mainly worked in various leading roles within the global medical device company Nobel Biocare. The roles include work as Senior Director Marketing and Product Management, Senior Regional Director North Europe, as well as Global Head Marketing, Customer Care, and Strategic Key Accounts.
Fredrik Strömberg has experience in developing product portfolios, processes and the offering in combination with commercial activities to achieve or exceed growth targets. Fredrik comes from a role as Senior Director Marketing and Product Management where he has been responsible for driving the business’s product portfolio strategy and commercialization regarding the core business of Nobel Biocare, i.e. the dental implant portfolio.
“We are extremely happy to welcome Fredrik Strömberg to Ortoma. With his solid experience in MedTech and his strong background in leadership, international sales and growth, Fredrik brings exactly the skills and strategic knowledge that Ortoma needs. We are in an extremely exciting phase in which I am convinced that Fredrik will contribute immensely. At the same time, I would like to take this opportunity to thank our acting CEO Anders Hahn for a fantastic job during the period he has shouldered responsibility for the business,” says Yvonne Mårtensson, chairman of the board.
“I am very happy and inspired to join Ortoma, a company at the forefront of medical device innovation. Ortoma’s advanced technology has the potential to revolutionize orthopedic surgery and improve the lives of patients worldwide. With my broad experience and deep understanding of the MedTech industry, I look forward to driving the company forward together with the team. Ortoma is facing a very exciting journey, and I am determined to contribute with my knowledge and commitment to maximize the company’s potential,” says Fredrik Strömberg.
For additional information, please contact:
Yvonne Mårtensson, Chairman of the Board, [email protected]
This information is information that Ortoma is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-25, 20:42 CET.
About Ortoma AB (publ)
Ortoma AB develops surgical systems for the planning and positioning of implants in hip, knee and spinal surgery. The purpose of the company’s surgical system, Ortoma Treatment Solution™ (OTS) is to enable surgeons to accurately measure and plan 3D surgery for the placement of joint implants, and during surgery, to optimally position the implant in the patient. Ortoma’s surgical system is aimed at providing better patient outcomes, fewer complications and less follow-up surgeries – and thus better long-term survival rates for implants. OTS is a system that is easily integrated into the processes and routines currently used in surgery, thereby increasing efficiency. Globally, more than 7.5 million orthopedic procedures are performed each year where OTS could be used in hip, knee and spinal surgery. In Sweden, around 42,000 surgical procedures were performed last year, involving hip, knee or spinal surgery. Ortoma’s B shares are listed on Nasdaq First North Growth Market Stockholm.